"Histones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each.
| Descriptor ID |
D006657
|
| MeSH Number(s) |
D12.776.157.687.485 D12.776.660.720.485 D12.776.664.469
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Histones".
Below are MeSH descriptors whose meaning is more specific than "Histones".
This graph shows the total number of publications written about "Histones" by people in this website by year, and whether "Histones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 4 | 3 | 7 |
| 2006 | 5 | 6 | 11 |
| 2007 | 3 | 5 | 8 |
| 2008 | 5 | 4 | 9 |
| 2009 | 4 | 8 | 12 |
| 2010 | 4 | 15 | 19 |
| 2011 | 3 | 15 | 18 |
| 2012 | 10 | 12 | 22 |
| 2013 | 7 | 12 | 19 |
| 2014 | 7 | 9 | 16 |
| 2015 | 7 | 11 | 18 |
| 2016 | 7 | 11 | 18 |
| 2017 | 12 | 10 | 22 |
| 2018 | 4 | 6 | 10 |
| 2019 | 7 | 8 | 15 |
| 2020 | 4 | 6 | 10 |
| 2021 | 3 | 5 | 8 |
| 2022 | 2 | 5 | 7 |
| 2023 | 3 | 3 | 6 |
| 2024 | 4 | 6 | 10 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Histones" by people in Profiles.
-
Biochemistry and regulation of histone lysine L-lactylation. Nat Rev Mol Cell Biol. 2026 Feb; 27(2):95-109.
-
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025 Sep; 645(8082):1051-1059.
-
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025 Jul 14; 16(1):522.
-
Binding mode-guided development of high-performance antibodies targeting site-specific posttranslational modifications. Proc Natl Acad Sci U S A. 2025 Jan 07; 122(1):e2411720121.
-
Evi1 governs Kdm6b-mediated histone demethylation to regulate the Laptm4b-driven mTOR pathway in hematopoietic progenitor cells. J Clin Invest. 2024 Dec 16; 134(24).
-
Central control of dynamic gene circuits governs T cell rest and activation. Nature. 2025 Jan; 637(8047):930-939.
-
RNA m5C oxidation by TET2 regulates chromatin state and leukaemogenesis. Nature. 2024 Oct; 634(8035):986-994.
-
Transcriptomic and proteomic spatial profiling of pediatric and adult diffuse midline glioma H3 K27-Altered. Sci Rep. 2024 09 30; 14(1):22668.
-
Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. Mol Cancer. 2024 Jun 10; 23(1):121.
-
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. J Med Chem. 2024 05 09; 67(9):6938-6951.